Kairos Pharma Ltd. has reported positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer, demonstrating significant clinical promise. Among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival exceeding 13 months, substantially surpassing the trial's target of a 45% improvement compared to the standard 3.7 months for second- or third-line hormone therapy.
The treatment's effectiveness is further evidenced by seven of nine patients showing declines in prostate-specific antigen levels, with five patients remaining on treatment. Importantly, the therapy was well tolerated with no dose-limiting toxicities observed, indicating a favorable safety profile for continued clinical development.
This development is significant because metastatic castration-resistant prostate cancer represents a critical unmet medical need where patients often develop resistance to standard therapies. ENV105, an antibody targeting CD105, addresses this challenge by targeting a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/BSLuY, elevation of CD105 in response to standard therapy results in resistance and disease relapse, making this approach potentially transformative for cancer treatment.
The implications extend beyond prostate cancer, as ENV105 is designed to restore the effectiveness of standard therapies across multiple cancer types. Kairos Pharma is currently conducting additional clinical trials, including a Phase 1 trial for lung cancer, demonstrating the broad potential application of their CD105-targeting technology. Investors and stakeholders can access additional company updates through https://ibn.fm/KAPA.
These interim results suggest that ENV105 could represent a new paradigm in oncology therapeutics by structurally addressing drug resistance mechanisms. The combination therapy's ability to significantly extend progression-free survival while maintaining tolerability positions it as a potential future standard of care for patients who have exhausted conventional treatment options.
